Context Therapeutics Stock Market Capitalization
| CNTX Stock | USD 1.36 0.03 2.16% |
Context Therapeutics fundamentals help investors to digest information that contributes to Context Therapeutics' financial success or failures. It also enables traders to predict the movement of Context Stock. The fundamental analysis module provides a way to measure Context Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Context Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Market Cap | 18 M | 17.1 M |
Context | Market Capitalization |
Context Therapeutics Company Market Capitalization Analysis
Context Therapeutics' Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Context Therapeutics Market Capitalization | 104.25 M |
Most of Context Therapeutics' fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Context Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Context Market Capitalization Driver Correlations
Understanding the fundamental principles of building solid financial models for Context Therapeutics is extremely important. It helps to project a fair market value of Context Stock properly, considering its historical fundamentals such as Market Capitalization. Since Context Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Context Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Context Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Context Market Capitalization Historical Pattern
Today, most investors in Context Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Context Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's market capitalization growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Context Therapeutics market capitalization as a starting point in their analysis.
Context Therapeutics Market Capitalization |
| Timeline |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
| Competition |
Based on the recorded statements, the market capitalization of Context Therapeutics is about 104.25 M. This is 99.19% lower than that of the Pharmaceuticals sector and 97.8% lower than that of the Health Care industry. The market capitalization for all United States stocks is 99.45% higher than that of the company.
Context Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Context Therapeutics' direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Context Therapeutics could also be used in its relative valuation, which is a method of valuing Context Therapeutics by comparing valuation metrics of similar companies.Context Therapeutics is currently under evaluation in market capitalization category among its peers.
Context Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 19.69 M | ||||
| Shares Outstanding | 75 M | ||||
| Shares Owned By Insiders | 1.44 % | ||||
| Shares Owned By Institutions | 76.40 % | ||||
| Number Of Shares Shorted | 802.81 K | ||||
| Price To Book | 1.24 X | ||||
| EBITDA | (25.06 M) | ||||
| Net Income | (23.96 M) | ||||
| Cash And Equivalents | 42.92 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 4.19 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 14.64 X | ||||
| Book Value Per Share | 0.74 X | ||||
| Cash Flow From Operations | (21.05 M) | ||||
| Short Ratio | 2.79 X | ||||
| Earnings Per Share | (0.88) X | ||||
| Target Price | 7.7 | ||||
| Beta | 2.25 | ||||
| Market Capitalization | 104.25 M | ||||
| Total Asset | 16.06 M | ||||
| Retained Earnings | (68.05 M) | ||||
| Working Capital | 11.86 M | ||||
| Net Asset | 16.06 M |
About Context Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Context Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Context Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Context Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.